DMRA
Price
$20.67
Change
+$0.44 (+2.17%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
1.28B
28 days until earnings call
Intraday BUY SELL Signals
NERV
Price
$3.28
Change
+$0.05 (+1.55%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
162.34M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMRA vs NERV

DMRA vs NERV Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMRA vs. NERV commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMRA is a Hold and NERV is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
DMRA vs NERV: Fundamental Ratings
DMRA
NERV
OUTLOOK RATING
1..100
5890
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
48
Fair valued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3665
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DMRA's Valuation (30) in the null industry is in the same range as NERV (48) in the Biotechnology industry. This means that DMRA’s stock grew similarly to NERV’s over the last 12 months.

DMRA's Profit vs Risk Rating (47) in the null industry is somewhat better than the same rating for NERV (100) in the Biotechnology industry. This means that DMRA’s stock grew somewhat faster than NERV’s over the last 12 months.

DMRA's SMR Rating (99) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that DMRA’s stock grew similarly to NERV’s over the last 12 months.

DMRA's Price Growth Rating (36) in the null industry is in the same range as NERV (65) in the Biotechnology industry. This means that DMRA’s stock grew similarly to NERV’s over the last 12 months.

NERV's P/E Growth Rating (98) in the Biotechnology industry is in the same range as DMRA (100) in the null industry. This means that NERV’s stock grew similarly to DMRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMRANERV
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (DMRA: $20.23 vs. NERV: $3.23)
Brand notoriety: DMRA and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMRA: 55% vs. NERV: 59%
Market capitalization -- DMRA: $1.28B vs. NERV: $162.34M
DMRA [@Biotechnology] is valued at $1.28B. NERV’s [@Biotechnology] market capitalization is $162.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMRA’s FA Score shows that 1 FA rating(s) are green while NERV’s FA Score has 0 green FA rating(s).

  • DMRA’s FA Score: 1 green, 4 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, DMRA is a better buy in the long-term than NERV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMRA’s TA Score shows that 4 TA indicator(s) are bullish while NERV’s TA Score has 4 bullish TA indicator(s).

  • DMRA’s TA Score: 4 bullish, 5 bearish.
  • NERV’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DMRA is a better buy in the short-term than NERV.

Price Growth

DMRA (@Biotechnology) experienced а -0.20% price change this week, while NERV (@Biotechnology) price change was -6.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.98%. For the same industry, the average monthly price growth was -14.69%, and the average quarterly price growth was -2.11%.

Reported Earning Dates

DMRA is expected to report earnings on Oct 30, 2026.

NERV is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMRA
Daily Signal:
Gain/Loss:
NERV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CRWG18.790.58
+3.19%
Leverage Shares 2X Long CRWV Daily ETF (CRWG)
MINN20.870.20
+0.94%
Mairs & Power Minnesota Municipal Bond ETF (MINN)
ARVR58.360.42
+0.73%
First Trust Indxx Metaverse ETF (ARVR)
FLTW109.15-0.10
-0.09%
Franklin FTSE Taiwan ETF (FLTW)
DWLD44.16-0.48
-1.08%
Davis Select Worldwide ETF (DWLD)

DMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMRA has been loosely correlated with COGT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DMRA jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMRA
1D Price
Change %
DMRA100%
-4.93%
COGT - DMRA
49%
Loosely correlated
-1.34%
NERV - DMRA
45%
Loosely correlated
-3.58%
INBX - DMRA
44%
Loosely correlated
-2.15%
RANI - DMRA
44%
Loosely correlated
+0.57%
GNTA - DMRA
38%
Loosely correlated
+14.80%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with DMRA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then DMRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-3.58%
DMRA - NERV
45%
Loosely correlated
-4.93%
ARMP - NERV
43%
Loosely correlated
-9.81%
ANRO - NERV
43%
Loosely correlated
-0.86%
SION - NERV
40%
Loosely correlated
-3.04%
DNLI - NERV
34%
Loosely correlated
-0.68%
More